Can Canafenib/Encofenib (Betavi) cure lung cancer and evaluation of its therapeutic effect

1. Overview of Canafenib

Canafenib (Encorafenib) is an oral BRAF inhibitor, mainly targeted at patients with non-small cell lung cancer (NSCLC) and melanoma who carry the BRAF V600E mutation. BRAF mutations are a type of driver gene mutation that can activate the downstream MEK/ERK signaling pathway, leading to rapid proliferation of tumor cells. Canafenib blocks this signaling pathway by selectively inhibiting BRAF kinase activity, thereby inhibiting tumor growth and inducing apoptosis. In clinical trials, canafenib is often used in combination with MEK inhibitors (such as binimetinib) to improve efficacy and delay the development of drug resistance.

2. The efficacy of canafenib in the treatment of lung cancer

Canafenib has shown better objective response rate (ORR) and progression-free survival (PFS) in patients with BRAF V600E mutated non-small cell lung cancer. Studies have shown that the objective response rate of canafenib alone can reach about 30%-40%, and when combined with a MEK inhibitor, the response rate can be increased to about 60%. In most patients, tumor volume reduction or lesion stabilization can be observed in the early stages of treatment.

However, it should be noted that canafenib cannot completely cure lung cancer. Since cancer itself is highly heterogeneous and drug-resistant, even if the initial response is significant, some patients may still develop disease progression or drug resistance within months to a year. Therefore, canafenib is clinically positioned more as a targeted therapy to control disease, extend survival, and improve quality of life, rather than as a radical therapy.

3. Resistance and treatment limitations of canafenib

During canafenib treatment, drug resistance is a problem that cannot be ignored. Lung cancer cells may be activated through the alternative signaling pathway, BRAF mutation expansion or MEKMechanisms such as pathway reactivation evade drug inhibition, resulting in decreased efficacy. This resistance phenomenon limits the curative potential of canafenib and also prompts patients and doctors to require regular imaging monitoring and molecular testing in order to detect disease progression in time and adjust treatment plans.

In addition, the efficacy of canafenib in the treatment of lung cancer is affected by many factors, including the patient's age, tumor stage, previous treatment history, combined underlying diseases , etc. If patients with early-stage lung cancer carry BRAF mutations and surgery is not feasible, canafenib can prolong progression-free survival; for patients with advanced or metastatic disease, the main goals are to delay disease progression and improve symptoms.

4. Practical application of canafenib in clinical practice

In real-world clinical practice, canafenib demonstrated a controllable safety profile and significant tumor suppression effect. Common side effects include rash, joint pain, fever, abnormal liver function and gastrointestinal reactions, most of which can be controlled through dose adjustment, symptomatic treatment or combination with MEK inhibitors. Patients should regularly monitor blood routine, liver and kidney function and electrocardiogram during use to detect and deal with adverse reactions in a timely manner.

In general, canafenib cannot achieve a radical cure for lung cancer, but within the scope of targeted therapy, it can significantly improve the survival and quality of life of patients, especially for patients with BRAF V600E mutations. Combined with clinical efficacy evaluation, resistance mechanism monitoring and individualized treatment adjustment, canafenib is an important treatment option for patients with non-small cell lung cancer, providing new treatment hope for patients who are inoperable or have limited effectiveness of traditional chemotherapy.

Reference materials:https://www.drugs.com/